Skip to Main Content
Skip Nav Destination

Immunotherapy Combo Key to Treating Some Liver Tumors

January 23, 2024

Abstract: Combining the PD-L1 inhibitor durvalumab and the angiogenesis inhibitor bevacizumab with transarterial chemoembolization can prolong progression-free survival in patients with inoperable hepatocellular carcinoma. However, ongoing trials may reveal an even more effective combination of checkpoint inhibitor with VGEF inhibitors plus TACE therapy for patients with liver cancer.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal